Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 436

1.

HIV viral load algorithm: what are the needs in the field?

Breton G, Laborde-Balen G, Guilavogui F, Karemangino S, Zana DK, Temgoua EM, Rouzioux C, Pizarro L, Tubiana R; ‘letʼs talk about failure’ working group.

AIDS. 2020 Jan 1;34(1):159-160. doi: 10.1097/QAD.0000000000002382. No abstract available.

PMID:
31693500
2.

Impact of Counseling Methods on HIV Retesting Uptake in At-Risk Individuals: A Randomized Controlled Study.

Salvadori N, Decker L, Ngo-Giang-Huong N, Mary JY, Chevret S, Arunothong S, Adam P, Khamduang W, Samleerat T, Luangsook P, Suksa-Ardphasu V, Achalapong J, Rouzioux C, Sirirungsi W, Jourdain G.

AIDS Behav. 2019 Oct 11. doi: 10.1007/s10461-019-02695-2. [Epub ahead of print]

PMID:
31605294
3.

False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers.

Hage-Sleiman M, Tremeaux P, Fillion M, Boufassa F, Melard A, Gardiennet E, Mariaggi AA, Plantier JC, Rouzioux C, Lambotte O, Avettand-Fenoel V; CODEX ANRS Cohort Study Group .

Clin Infect Dis. 2019 Sep 21. pii: ciz734. doi: 10.1093/cid/ciz734. [Epub ahead of print]

PMID:
31541253
4.

Cell and tissue reservoirs of HIV-1: dynamics during infection.

Trémeaux P, Rouzioux C, Avettand-Fènoël V.

Virologie (Montrouge). 2019 Aug 1;23(4):211-228. doi: 10.1684/vir.2019.0784.

PMID:
31414659
5.

Genital Human Immunodeficiency Virus-1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials.

Hocqueloux L, Gubavu C, Prazuck T, De Dieuleveult B, Guinard J, Sève A, Mille C, Gardiennet E, Lopez P, Rouzioux C, Lefeuvre S, Avettand-Fènoël V.

Clin Infect Dis. 2019 Jul 11. pii: ciz511. doi: 10.1093/cid/ciz511. [Epub ahead of print]

PMID:
31350995
6.

HIV-mediated immune aging in young adults infected perinatally or during childhood.

Fastenackels S, Sauce D, Vigouroux C, Avettand-Fènoël V, Bastard JP, Fellahi S, Nailler L, Arezes E, Rouzioux C, Warszawski J, Viard JP, Appay V; ANRS Co19 COVERTE Study Group.

AIDS. 2019 Sep 1;33(11):1705-1710. doi: 10.1097/QAD.0000000000002275.

PMID:
31149945
7.

Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection.

Trémeaux P, Lenfant T, Boufassa F, Essat A, Mélard A, Gousset M, Delelis O, Viard JP, Bary M, Goujard C, Rouzioux C, Meyer L, Avettand-Fenoel V; ANRS-SEROCO and PRIMO cohorts.

EBioMedicine. 2019 Mar;41:455-464. doi: 10.1016/j.ebiom.2019.02.016. Epub 2019 Feb 23.

8.

Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.

Kula A, Delacourt N, Bouchat S, Darcis G, Avettand-Fenoel V, Verdikt R, Corazza F, Necsoi C, Vanhulle C, Bendoumou M, Burny A, De Wit S, Rouzioux C, Rohr O, Van Lint C.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):605-613. doi: 10.1097/QAI.0000000000001958.

PMID:
30768485
9.

Dynamics in HIV-DNA levels over time in HIV controllers.

Avettand-Fenoel V, Bayan T, Gardiennet E, Boufassa F, Lopez P, Lecuroux C, Noel N, Trémeaux P, Monceaux V, Autran B, Meyer L, Saez-Cirion A, Lambotte O, Rouzioux C; CODEX ANRS Cohort Study Group.

J Int AIDS Soc. 2019 Jan;22(1):e25221. doi: 10.1002/jia2.25221.

10.

Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains.

Avettand-Fénoël V, Mélard A, Gueudin M, Maillard A, Dina J, Gousset M, Chaix ML, Lerolle N, Viard JP, Meyer L, Plantier JC, Rouzioux C; ANRS-AC11 HIV Quantification Working Group.

J Clin Virol. 2019 Jan;110:36-41. doi: 10.1016/j.jcv.2018.12.002. Epub 2018 Dec 3.

PMID:
30530097
11.

Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.

Sarracino A, Gharu L, Kula A, Pasternak AO, Avettand-Fenoel V, Rouzioux C, Bardina M, De Wit S, Benkirane M, Berkhout B, Van Lint C, Marcello A.

MBio. 2018 Nov 13;9(6). pii: e02158-18. doi: 10.1128/mBio.02158-18.

12.

HIV DNA: a clinical marker of HIV reservoirs.

Rouzioux C, Trémeaux P, Avettand-Fenoël V.

Curr Opin HIV AIDS. 2018 Sep;13(5):389-394. doi: 10.1097/COH.0000000000000483. Review.

PMID:
30020275
13.

Total HIV DNA: a global marker of HIV persistence.

Rouzioux C, Avettand-Fenoël V.

Retrovirology. 2018 Apr 3;15(1):30. doi: 10.1186/s12977-018-0412-7. Review.

14.

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.

Pressiat C, Hirt D, Treluyer JM, Zheng Y, Morlat P, Naqvi A, Tran L, Viard JP, Avettand-Fenoel V, Rouzioux C, Meyer L, Cheret A; OPTIPRIM Study Group.

J Antimicrob Chemother. 2018 Apr 1;73(4):1020-1024. doi: 10.1093/jac/dkx498.

PMID:
29365125
15.

What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM.

Bendenoun M, Samri A, Avettand-Fènoël V, Cardinaud S, Descours B, Carcelain G, Mazeron MC, Bergmann JF, Urrutia A, Moris A, Rouzioux C, Simon F, Andre P, Pocard M, Dray X, Mourez T, Vieillard V, Autran B, Barin F, Sellier P.

EBioMedicine. 2018 Jan;27:51-60. doi: 10.1016/j.ebiom.2017.12.003. Epub 2017 Dec 7.

16.

Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection.

Novelli S, Lécuroux C, Avettand-Fenoel V, Seng R, Essat A, Morlat P, Viard JP, Rouzioux C, Meyer L, Goujard C.

Clin Infect Dis. 2018 May 2;66(10):1519-1527. doi: 10.1093/cid/cix1068.

PMID:
29211834
17.

Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.

Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group.

Lancet Glob Health. 2017 Nov;5(11):e1080-e1089. doi: 10.1016/S2214-109X(17)30372-8.

18.

Diagnosis and treatment of HIV primary infection: the earlier, the better !

Rouzioux C, Avettand-Fénoël V, Cheret A.

Rev Prat. 2017 Oct;67(8):892-895. French.

PMID:
30512824
19.

NKG2C+ memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147.

Gondois-Rey F, Chéret A, Granjeaud S, Mallet F, Bidaut G, Lécuroux C, Ploquin M, Müller-Trutwin M, Rouzioux C, Avettand-Fenoël V, Moretta A, Pialoux G, Goujard C, Meyer L, Olive D.

Clin Transl Immunology. 2017 Jul 7;6(7):e150. doi: 10.1038/cti.2017.22. eCollection 2017 Jul.

20.

Impact of early cART on HIV blood and semen compartments at the time of primary infection.

Chéret A, Durier C, Mélard A, Ploquin M, Heitzmann J, Lécuroux C, Avettand-Fenoël V, David L, Pialoux G, Chennebault JM, Müller-Trutwin M, Goujard C, Rouzioux C, Meyer L; ANRS OPTIPRIM study group.

PLoS One. 2017 Jul 14;12(7):e0180191. doi: 10.1371/journal.pone.0180191. eCollection 2017.

21.

New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.

Bertine M, Gueudin M, Mélard A, Damond F, Descamps D, Matheron S, Collin F, Rouzioux C, Plantier JC, Avettand-Fenoel V.

J Clin Microbiol. 2017 Sep;55(9):2850-2857. doi: 10.1128/JCM.00755-17. Epub 2017 Jul 12.

22.

Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies.

Gantner P, Mélard A, Damond F, Delaugerre C, Dina J, Gueudin M, Maillard A, Sauné K, Rodallec A, Tuaillon E, Plantier JC, Rouzioux C, Avettand-Fenoel V; ANRS-AC11 Quantification Working Group.

J Med Virol. 2017 Nov;89(11):2047-2050. doi: 10.1002/jmv.24874. Epub 2017 Jul 6.

PMID:
28617961
23.

HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.

Rouers A, Klingler J, Su B, Samri A, Laumond G, Even S, Avettand-Fenoel V, Richetta C, Paul N, Boufassa F, Hocqueloux L, Mouquet H, Rouzioux C, Lambotte O, Autran B, Graff-Dubois S, Moog C, Moris A; ANRS CO21 Cohort.

EBioMedicine. 2017 Jul;21:158-169. doi: 10.1016/j.ebiom.2017.05.029. Epub 2017 May 31.

24.

A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level.

Canouï E, Lécuroux C, Avettand-Fenoël V, Gousset M, Rouzioux C, Saez-Cirion A, Meyer L, Boufassa F, Lambotte O, Noël N; and the ANRS CO21 CODEX Study Group.

Open Forum Infect Dis. 2017 Apr 3;4(2):ofx064. doi: 10.1093/ofid/ofx064. eCollection 2017 Spring.

25.

Gag-Specific CD8 T-Cell Proliferation Is Associated With Higher Peripheral Blood Levels of Transforming Growth Factor-β and Gut-Homing T Cells in Youths Perinatally Infected With Human Immunodeficiency Virus-1: The ANRS-EP38-IMMIP Study.

Warszawski J, Avettand-Fenoel V, Rouzioux C, Scott-Algara D, Montange T, Didier C, Le Chenadec J, Viard JP, Dollfus C, Blanche S, Buseyne F.

Open Forum Infect Dis. 2016 Dec 7;4(1):ofw239. doi: 10.1093/ofid/ofw239. eCollection 2017 Winter.

26.

Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.

Amani-Bosse C, Dahourou DL, Malateste K, Amorissani-Folquet M, Coulibaly M, Dattez S, Emieme A, Barry M, Rouzioux C, N'gbeche S, Yonaba C, Timité-Konan M, Mea V, Ouédraogo S, Blanche S, Meda N, Seguin-Devaux C, Leroy V.

J Int AIDS Soc. 2017 Apr 25;20(1):21362. doi: 10.7448/IAS.20.01.21362.

27.

Cytomegalovirus infection in HIV-infected versus non-infected infants and HIV disease progression in Cytomegalovirus infected versus non infected infants early treated with cART in the ANRS 12140-Pediacam study in Cameroon.

Kfutwah AK, Ngoupo PA, Sofeu CL, Ndongo FA, Guemkam G, Ndiang ST, Owona F, Penda IC, Tchendjou P, Rouzioux C, Warszawski J, Faye A, Tejiokem MC.

BMC Infect Dis. 2017 Mar 23;17(1):224. doi: 10.1186/s12879-017-2308-x.

28.

A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART.

Gondois-Rey F, Chéret A, Mallet F, Bidaut G, Granjeaud S, Lécuroux C, Ploquin M, Müller-Trutwin M, Rouzioux C, Avettand-Fenoël V, De Maria A, Pialoux G, Goujard C, Meyer L, Olive D.

Front Immunol. 2017 Feb 10;8:54. doi: 10.3389/fimmu.2017.00054. eCollection 2017.

29.

Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies.

Chaillon A, Essat A, Frange P, Smith DM, Delaugerre C, Barin F, Ghosn J, Pialoux G, Robineau O, Rouzioux C, Goujard C, Meyer L, Chaix ML; on behalf the ANRS PRIMO Cohort Study.

Retrovirology. 2017 Feb 21;14(1):15. doi: 10.1186/s12977-017-0339-4.

30.

HIV Infection in the Native and Allograft Kidney: Implications for Management, Diagnosis, and Transplantation.

Avettand-Fenoël V, Rouzioux C, Legendre C, Canaud G.

Transplantation. 2017 Sep;101(9):2003-2008. doi: 10.1097/TP.0000000000001674. Review.

PMID:
28196049
31.

Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.

Valade E, Bouazza N, Lui G, Illamola SM, Benaboud S, Treluyer JM, Cobat A, Foissac F, De Sousa Mendes M, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Urien S, Ghosn J, Hirt D.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02062-16. doi: 10.1128/AAC.02062-16. Print 2017 Mar.

32.

Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.

Darcis G, Bouchat S, Kula A, Van Driessche B, Delacourt N, Vanhulle C, Avettand-Fenoel V, De Wit S, Rohr O, Rouzioux C, Van Lint C.

AIDS. 2017 Jan 14;31(2):181-189. doi: 10.1097/QAD.0000000000001290.

PMID:
27755105
33.

Gag-Specific CD4 T Cell Proliferation, Plasmacytoid Dendritic Cells, and Ethnicity in Perinatally HIV-1-Infected Youths: The ANRS-EP38-IMMIP Study.

Scott-Algara D, Warszawski J, Chenadec JL, Didier C, Montange T, Viard JP, Dollfus C, Avettand-Fenoel V, Rouzioux C, Blanche S, Buseyne F.

AIDS Res Hum Retroviruses. 2017 Jan;33(1):21-28. doi: 10.1089/AID.2016.0177. Epub 2016 Oct 12.

34.

Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Avettand-Fènoël V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, Viard JP, Rouzioux C.

Clin Microbiol Rev. 2016 Oct;29(4):859-80. doi: 10.1128/CMR.00015-16. Review.

35.

Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset.

Ploquin MJ, Madec Y, Casrouge A, Huot N, Passaes C, Lécuroux C, Essat A, Boufassa F, Jacquelin B, Jochems SP, Petitjean G, Angin M, Gärtner K, Garcia-Tellez T, Noël N, Booiman T, Boeser-Nunnink BD, Roques P, Saez-Cirion A, Vaslin B, Dereudre-Bosquet N, Barré-Sinoussi F, Ghislain M, Rouzioux C, Lambotte O, Albert ML, Goujard C, Kootstra N, Meyer L, Müller-Trutwin MC.

PLoS Pathog. 2016 Aug 10;12(8):e1005774. doi: 10.1371/journal.ppat.1005774. eCollection 2016 Aug.

36.

HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens.

Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D, Rouzioux C, Ghosn J; EVARIST ANRS EP 49 Study Group.

J Antimicrob Chemother. 2016 Nov;71(11):3202-3205. Epub 2016 Jul 17.

PMID:
27432601
37.

Polyfunctional HIV-specific T cells in Post-Treatment Controllers.

Samri A, Bacchus-Souffan C, Hocqueloux L, Avettand-Fenoel V, Descours B, Theodorou I, Larsen M, Saez-Cirion A, Rouzioux C, Autran B; ANRS VISCONTI study group.

AIDS. 2016 Sep 24;30(15):2299-302. doi: 10.1097/QAD.0000000000001195.

PMID:
27428742
38.

Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, Lecuroux C, Rouzioux C, Boufassa F, Pancino G, Venet A, Van Lint C, Martinez-Picado J, Lambotte O, Sáez-Cirión A, Prado JG.

J Virol. 2016 Jun 10;90(13):6148-6158. doi: 10.1128/JVI.00419-16. Print 2016 Jul 1.

39.

Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line.

Kumar A, Abbas W, Colin L, Khan KA, Bouchat S, Varin A, Larbi A, Gatot JS, Kabeya K, Vanhulle C, Delacourt N, Pasquereau S, Coquard L, Borch A, König R, Clumeck N, De Wit S, Rohr O, Rouzioux C, Fulop T, Van Lint C, Herbein G.

Sci Rep. 2016 Apr 14;6:24090. doi: 10.1038/srep24090.

40.

Estimation of HIV-1 DNA Level Interfering with Reliability of HIV-1 RNA Quantification Performed on Dried Blood Spots Collected from Successfully Treated Patients.

Zida S, Tuaillon E, Barro M, Kwimatouo Lekpa Franchard A, Kagoné T, Nacro B, Ouedraogo AS, Bolloré K, Sanosyan A, Plantier JC, Meda N, Sangaré L, Rouzioux C, Rouet F, Kania D.

J Clin Microbiol. 2016 Jun;54(6):1641-1643. doi: 10.1128/JCM.03372-15. Epub 2016 Mar 23.

41.

HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.

Frange P, Faye A, Avettand-Fenoël V, Bellaton E, Descamps D, Angin M, David A, Caillat-Zucman S, Peytavin G, Dollfus C, Le Chenadec J, Warszawski J, Rouzioux C, Sáez-Cirión A; ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group.

Lancet HIV. 2016 Jan;3(1):e49-54. doi: 10.1016/S2352-3018(15)00232-5. Epub 2015 Dec 9.

42.

Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.

Bouchat S, Delacourt N, Kula A, Darcis G, Van Driessche B, Corazza F, Gatot JS, Melard A, Vanhulle C, Kabeya K, Pardons M, Avettand-Fenoel V, Clumeck N, De Wit S, Rohr O, Rouzioux C, Van Lint C.

EMBO Mol Med. 2016 Feb 1;8(2):117-38. doi: 10.15252/emmm.201505557.

43.

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.

Gantner P, Morand-Joubert L, Sueur C, Raffi F, Fagard C, Lascoux-Combe C, Salmon D, Amiel C, Lambert-Niclot S, Fofana DB, Viard JP, Fafi-Kremer S, Rouzioux C, Avettand-Fenoel V, Ghosn J.

J Antimicrob Chemother. 2016 Mar;71(3):751-61. doi: 10.1093/jac/dkv395. Epub 2015 Dec 16.

PMID:
26676973
44.

Gag-Specific CD4 and CD8 T-Cell Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is Associated with Ethnicity - The ANRS-EP38-IMMIP Study.

Le Chenadec J, Scott-Algara D, Blanche S, Didier C, Montange T, Viard JP, Dollfus C, Avettand-Fenoel V, Rouzioux C, Warszawski J, Buseyne F.

PLoS One. 2015 Dec 9;10(12):e0144706. doi: 10.1371/journal.pone.0144706. eCollection 2015.

45.

Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).

Piroth L, Moinot L, Yeni P, Avettand-Fénoel V, Reynes J, Girard PM, Marchou B, Georget A, Rouzioux C, Autran B, Duvillard L, Chêne G, Fagard C; ANRS 141 TIPI Trial Study Group.

J Antimicrob Chemother. 2016 Feb;71(2):490-6. doi: 10.1093/jac/dkv369. Epub 2015 Nov 14.

PMID:
26568566
46.

Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection.

Damouche A, Lazure T, Avettand-Fènoël V, Huot N, Dejucq-Rainsford N, Satie AP, Mélard A, David L, Gommet C, Ghosn J, Noel N, Pourcher G, Martinez V, Benoist S, Béréziat V, Cosma A, Favier B, Vaslin B, Rouzioux C, Capeau J, Müller-Trutwin M, Dereuddre-Bosquet N, Le Grand R, Lambotte O, Bourgeois C.

PLoS Pathog. 2015 Sep 24;11(9):e1005153. doi: 10.1371/journal.ppat.1005153. eCollection 2015 Sep.

47.

A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.

Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard PM, Rouzioux C, Costagliola D; ANRS 116 SALTO study group.

AIDS. 2015 Sep 24;29(15):2003-7. doi: 10.1097/QAD.0000000000000734.

PMID:
26355572
48.

Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.

Valade E, Tréluyer JM, Illamola SM, Bouazza N, Foissac F, De Sousa Mendes M, Lui G, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Hirt D, Urien S, Ghosn J; Evarist ANRS-EP 49 Study Group.

Antimicrob Agents Chemother. 2015 Nov;59(11):6800-6. doi: 10.1128/AAC.01517-15. Epub 2015 Aug 17.

49.

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.

PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063. eCollection 2015 Jul.

50.

No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.

Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, Matheron S, Khuong MA, Garrait V, Reliquet V, Devidas A, Berrebi A, Allisy C, Elleau C, Arvieux C, Rouzioux C, Warszawski J, Blanche S; ANRS-EPF Study Group.

Clin Infect Dis. 2015 Dec 1;61(11):1715-25. doi: 10.1093/cid/civ578. Epub 2015 Jul 21.

PMID:
26197844

Supplemental Content

Loading ...
Support Center